The cancer checkpoint blockade with inhibitors that target the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) pathway have demonstrated promising results for a wide variety of tumors (9, 10). This evidence concerns the gene PDCD1 and cancer.